We studied 479 epileptic patients. The study included the evaluation of anamnesis, clinical and neurological examination, routine EEG and/or video-EEG-monitoring, MRI of the brain. The period of observation was 1-8 years (on average 2.5 years). Idiopathic generalized epilepsy was diagnosed in 55 cases, cryptogenic focal epilepsy in 228 cases and symptomatic focal epilepsy in 196 cases. In the end of study, remission was achieved in 29.2%, the serious reduction in the number of seizures in 31.7%, no effect was seen in 39.1%. There were 261 attempts of therapy with carbamazepine (CBZ), 298 with valproates (VPA), 173 with topiramate (TPM), 48 with levetiracetam (LEV), 18 with lamotrigine (LTG), 23 with benzodiazepines (BDZ), 62 with barbiturates (BRB), 3 with ethosuximide (ESM), 15 with oxcarbazepine (OXC), 1 with lacosamide (LAS) and 8 with phenytoin (PHT). The total efficacy (remission plus seizure reduction) was similar for VPA (48%), TPM (47.4%) and CBZ (44.5%). Stopping treatment due to adverse effects was significantly higher in TPM (12,1%) versus LEV (4,2%) (p<0,05).